论文部分内容阅读
目的:探讨中成药所致肝损害的相关药物、发病机制及防治。方法:对本院1991-2003年收治的103例中成药所致肝炎进行统计,从发病趋势、相关药物、临床表现、治疗及预后几个方面进行分析。结果:中成药所致药物性肝炎,以治疗骨关节病药物占首位,其次为皮肤病用药。临床表现以肝细胞损害为主,也有表现为胆汁淤积型肝炎者。经西药或中西医结合治疗后,绝大部分痊愈和好转。结论:中成药所致肝损害集中发生于治疗骨关节病与皮肤病两类药物,表明该两类药物可能含有某些肝毒性成分或者与配伍等因素相关,确切机制有待于进一步研究。加强临床监测和信息交流有助于及时发现及预防肝损害的发生。
Objective: To investigate the related drugs, pathogenesis and prevention and treatment of liver damage caused by proprietary Chinese medicines. Methods: The statistics of hepatitis caused by 103 Chinese patent medicines admitted in our hospital from 1991 to 2003 were analyzed, and the incidence trends, related drugs, clinical manifestations, treatment and prognosis were analyzed. Results: Chinese medicine-induced drug-induced hepatitis, to treat osteoarthritis drugs tops, followed by dermatological medication. Clinical manifestations of liver cell damage, there are also manifested as cholestatic hepatitis. After Western medicine or Integrative Medicine, the vast majority of recovery and improvement. Conclusion: The liver damage caused by proprietary Chinese medicine (TCM) occurred mainly in the treatment of osteoarthritis and dermatosis. These two drugs may contain some hepatotoxicity components or may be related to compatibility and other factors. The exact mechanism remains to be further studied. Strengthening clinical monitoring and information exchange will help detect and prevent the occurrence of liver damage in time.